Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Parallel-group, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Oral Tropifexor (LJN452) & Licogliflozin (LIK066) Combination Therapy and Each Monotherapy, Compared With Placebo for Treatment of Adult Patients With Nonalcoholic Steatohepatitis (NASH) and Liver Fibrosis.(ELIVATE)
Conditions
Interventions
Tropifexor
Licogliflozin
+1 more
Locations
80
United States
Gut PC Digestive Health Specialist
Dothan, Alabama, United States
Southern California Research Center
Coronado, California, United States
Velocity Clinical Trials
Los Angeles, California, United States
California Liver Research Institute
Pasadena, California, United States
Medical Associates Research Group
San Diego, California, United States
San fernando Valley Health Institute
Van Nuys, California, United States
Start Date
December 30, 2019
Primary Completion Date
October 27, 2022
Completion Date
October 27, 2022
Last Updated
January 28, 2025
NCT04052516
NCT02548351
NCT04880187
NCT02098317
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions